Ajanta Pharma shares fall 1.3%, among top losers on Nifty Midcap 150 in early trade

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Shares of Ajanta Pharma were trading down by 1.3% at Rs 2,580.00 in early trade on Monday, making it one of the top losers on the Nifty Midcap 150 index. Other stocks that saw losses include Sundaram Fin, New India Assur, Endurance Techn and Supreme Ind.

Ajanta Pharma's revenue for the quarter ending June 2025 stood at Rs 1,302.65 Crore, compared to Rs 1,144.92 Crore in June 2024, marking an increase. The net profit for the same period was Rs 255.34 Crore, up from Rs 245.77 Crore in the corresponding quarter of the previous year. The EPS for June 2025 was Rs 20.44, compared to Rs 19.54 in June 2024.

Looking at the yearly data, Ajanta Pharma's revenue for the year ending March 2025 was Rs 4,648.10 Crore, up from Rs 4,208.71 Crore in March 2024. The net profit increased to Rs 920.39 Crore from Rs 816.17 Crore. The EPS stood at 73.56, compared to 64.82 in the previous year. The company’s debt-to-equity ratio remained at 0.00 for the year ending March 2025.

Ajanta Pharma announced several dividends, including an interim dividend of Rs 28.00 per share (1400%) with an effective date of November 6, 2024. The company also had a bonus issue on May 10, 2022, with a bonus ratio of 1:2, and a stock split on January 28, 2015, changing the face value from Rs 5 to Rs 2.

Moneycontrol analysis on September 4, 2025, indicated a bearish sentiment for the stock.

With the stock currently trading at Rs 2,580.00, Ajanta Pharma is facing selling pressure in today's session, joining other stocks in the Nifty Midcap 150 index that are experiencing declines.